Antiviral Therapy

Papers
(The median citation count of Antiviral Therapy is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection44
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective30
The making of the one pill—Developing single tablet regimens for HIV and for HCV23
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting20
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts16
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation16
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants16
Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam14
Commentary: John C. Martin (1951–2021)13
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study13
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity12
A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir12
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway11
Tenofovir alafenamide fumarate11
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir10
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud9
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report9
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines9
A favipiravir-induced angioedema and urticaria in a COVID-19 patient8
Pharmacokinetic and mass balance characterization of [ 14 C] RAY1216, a SARS-CoV-2 M pro inhibitor, in healthy Chinese male subjec7
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study7
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review7
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database6
The transformation of HIV therapy: One pill once a day6
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis6
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach6
Lipid and glucose abnormalities and associated factors among children living with HIV in Asia5
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)5
Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study5
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine5
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis5
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort5
The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis5
Antiviral potential of phenolic compounds against HSV-1: In-vitro study4
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C4
Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case–control study from Uganda and South Africa4
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ4
Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor4
Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV4
Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobu3
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV3
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives3
Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy3
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report3
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-193
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B3
Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive t3
The curing regimens of HCV: A SWOT analysis3
Preface: Special Collection Commemorating John C. Martin3
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case3
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study3
0.12805414199829